Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - RADIENT PHARMACEUTICALS Corp | v239435_ex99-1.htm |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 ACT REPORTING REQUIREMENTS
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
Date of Report (Date of Earliest Event Reported): November 7, 2011
Radient Pharmaceuticals Corporation
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-16695
|
33-0413161
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
2492 Walnut Avenue, Suite 100, Tustin, California, 92780-7039
(Address of principal executive offices (zip code))
714-505-4461
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a - 12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
Section 5
Item 5.07– Submission of Matters to a Vote of Security Holders
On November 4, 2011, we held a Special Shareholder’s meeting whereby all six proposals contained in the Definitive 14A filed on October 14, 2011 passed.
Section 7
Item 7.01-Regulation FD Disclosure
On November 4, 2011, we also filed a Press Release announcing the results of the shareholder’s meeting, a copy of which is attached hereto.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
|
Exhibit No.
|
Description
|
| 99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
RADIENT PHARMACEUTICALS CORPORATION
By: /s/ Akio Ariura
Name: Akio Ariura
Title: Chief Financial Officer
Dated: November 7, 2011